Lyell Immunopharma, Inc. Cash And Cash Equivalents At Carrying Value

Quick Answer

Lyell Immunopharma, Inc. reported Cash And Cash Equivalents At Carrying Value of $60.18 million for the year ending 2025.

  • Lyell Immunopharma, Inc. showed a decrease of -43.0% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from Lyell Immunopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
  • XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 7 years of available data (2019 to 2025), Lyell Immunopharma, Inc.'s Cash And Cash Equivalents At Carrying Value has declined by 37.7%.
  • Historical annual values: Fiscal year 2025: $60.18 million | Fiscal year 2024: $105.60 million | Fiscal year 2023: $145.65 million | Fiscal year 2022: $123.55 million | Fiscal year 2021: $293.83 million | Fiscal year 2020: $140.41 million | Fiscal year 2019: $96.67 million.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: